Market Update (NASDAQ:GILD): Health Canada Issues Notice of Compliance for Gilead’s Single Tablet Regimen Genvoya™ (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

[CNW Group] – Health Canada Issues Notice of Compliance for Gilead’s Single Tablet Regimen Genvoya™ (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection Read more on this. Gilead Sciences . . . → Read More: Market Update (NASDAQ:GILD): Health Canada Issues Notice of Compliance for Gilead’s Single Tablet Regimen Genvoya™ (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection Similar Articles: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults